Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
By A. Kastrati, J. Mehilli, F. Neumann, F. Dotzer, J. T. ten Berg, H. Bollwein, Isolde Graf, Maryam Ibrahim, J. Pache, M. Seyfarth and 4 more. Journal of the American Medical Association (JAMA), 2006
786 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/2006a4c41c1f082603cb042fb870e7d362dcf929
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “• Aspirin maintenance dose continued indefinitely 81 mg/d–162 mg/d I A (142-144)”
- Guidelines on myocardial revascularization. (2010, background): “patients [249] and might therefore be preferred over”
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “, elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI (206,207).”